Robert L Coffman
Overview
Explore the profile of Robert L Coffman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
6539
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Strohmeier S, Amanat F, Campbell J, Traquina P, Coffman R, Krammer F
NPJ Vaccines
. 2022 Jul;
7(1):81.
PMID: 35869085
Influenza virus infections pose a significant threat to global health. Vaccination is the main countermeasure against influenza virus spread, however, the effectiveness of vaccines is variable. Current seasonal influenza virus...
2.
Grigoryan L, Lee A, Walls A, Lai L, Franco B, Arunachalam P, et al.
NPJ Vaccines
. 2022 May;
7(1):55.
PMID: 35606518
Adjuvants enhance the magnitude and the durability of the immune response to vaccines. However, there is a paucity of comparative studies on the nature of the immune responses stimulated by...
3.
Jankovic D, Ciucci T, Coffman R, Coquet J, Le Gros G, Mosmann T, et al.
Nat Immunol
. 2022 Feb;
23(4):501-502.
PMID: 35190720
No abstract available.
4.
Garon E, Spira A, Johnson M, Bazhenova L, Leach J, Cummings A, et al.
Clin Cancer Res
. 2021 Jun;
27(16):4566-4573.
PMID: 34108179
Purpose: Although PD-(L)1 inhibitors have shown efficacy in advanced/metastatic non-small cell lung cancer (NSCLC), many patients do not respond to this treatment and more effective combinations with acceptable toxicities are...
5.
Arunachalam P, Walls A, Golden N, Atyeo C, Fischinger S, Li C, et al.
Nature
. 2021 Apr;
594(7862):253-258.
PMID: 33873199
The development of a portfolio of COVID-19 vaccines to vaccinate the global population remains an urgent public health imperative. Here we demonstrate the capacity of a subunit vaccine, comprising the...
6.
Arunachalam P, Walls A, Golden N, Atyeo C, Fischinger S, Li C, et al.
bioRxiv
. 2021 Feb;
PMID: 33594366
The development of a portfolio of SARS-CoV-2 vaccines to vaccinate the global population remains an urgent public health imperative. Here, we demonstrate the capacity of a subunit vaccine under clinical...
7.
Kuo T, Lin M, Coffman R, Campbell J, Traquina P, Lin Y, et al.
Sci Rep
. 2020 Nov;
10(1):20085.
PMID: 33208827
The COVID-19 pandemic is a worldwide health emergency which calls for an unprecedented race for vaccines and treatment. In developing a COVID-19 vaccine, we applied technology previously used for MERS-CoV...
8.
Psallidas I, Backer V, Kuna P, Palmer R, Necander S, Aurell M, et al.
Am J Respir Crit Care Med
. 2020 Aug;
203(3):296-306.
PMID: 32809843
To examine the potential of TLR9 (Toll-like receptor 9) activation to modulate the type 2 immune response in asthma. To evaluate efficacy and safety of AZD1419, an inhaled TLR9 agonist,...
9.
Leong W, Ames R, Haverkamp J, Torres L, Kline J, Bans A, et al.
Oncotarget
. 2020 Jan;
10(68):7220-7237.
PMID: 31921384
The synthetic oligonucleotide SD-101 is a potent and specific agonist for toll-like receptor 9. Intratumoral injection of SD-101 induces significant anti-tumor immunity in preclinical and clinical studies, especially when combined...
10.
Kell S, Kachura M, Renn A, Traquina P, Coffman R, Campbell J
Int Immunopharmacol
. 2018 Dec;
66:296-308.
PMID: 30502651
CpG-motif-containing oligodeoxynucleotides (CpG-ODN) activate innate immunity through Toll-Like Receptor (TLR) 9 signaling and generate local immune responses when delivered directly to the lung. Herein we describe pharmacological studies in mice,...